Our Services
Medical Information
Helpful Resources
Published on: 4/4/2026
Guanfacine safety in pregnancy is based on limited human data, so decisions should be individualized with your clinician; it is typically used only when benefits outweigh risks, is not usually first line for blood pressure, and it should not be stopped abruptly due to rebound effects.
Possible concerns include maternal low blood pressure and dizziness, and if taken late in pregnancy newborns may need monitoring for sleepiness, low heart rate, or feeding issues. There are several factors to consider, including ADHD symptom control, alternatives, monitoring, and breastfeeding; see the complete details below to help guide your next steps.
If you are pregnant — or planning to become pregnant — and taking guanfacine for ADHD or high blood pressure, it's normal to have questions. You want to manage your health while also protecting your baby. This article explains what we currently know about guanfacine safety in pregnancy, including potential risks, benefits, and important considerations.
Because research in pregnant women is limited, decisions about continuing or stopping guanfacine must always be made carefully and with medical guidance.
Guanfacine is a medication that works on alpha-2A adrenergic receptors in the brain. It is commonly prescribed for:
It works by calming certain nerve signals. In ADHD, this can improve focus, impulse control, and emotional regulation. For blood pressure, it lowers heart rate and relaxes blood vessels.
Understanding guanfacine side effects is important during pregnancy because some of these effects can overlap with normal pregnancy symptoms.
Common side effects include:
Less common but more serious side effects can include:
During pregnancy, low blood pressure and dizziness can increase fall risk, which is something to monitor carefully.
There are limited human studies evaluating guanfacine use in pregnancy. Most available data comes from:
Animal studies have not consistently shown major birth defects, but animal research does not always predict human outcomes.
Because of limited human data, guanfacine is generally prescribed in pregnancy only if the benefits outweigh the potential risks.
There is no strong evidence that guanfacine causes major birth defects. However, due to limited data, doctors remain cautious.
Possible concerns include:
Newborn monitoring may be recommended if guanfacine is used in the third trimester. Babies may be observed for:
These effects, if they occur, are usually temporary but require medical supervision.
ADHD does not disappear during pregnancy. In fact, symptoms can sometimes feel worse due to:
Untreated ADHD may affect:
For some women, stopping medication leads to significant difficulty functioning. For others, symptoms may be manageable with non-medication strategies.
If you're experiencing symptoms and want to better understand whether they align with Attention Deficit Hyperactivity Disorder (ADHD), a free online assessment can help you identify patterns and prepare for more informed conversations with your healthcare provider.
Treatment decisions depend on severity.
Possible approaches include:
Sometimes a doctor may:
No ADHD medication is considered completely risk-free in pregnancy. Each option requires individualized evaluation.
When guanfacine is used for hypertension, the situation may be different.
Uncontrolled high blood pressure during pregnancy can lead to:
In these cases, controlling blood pressure is critical. However, guanfacine is not usually a first-line blood pressure medication in pregnancy. Other medications have more established safety data.
If guanfacine is being used for blood pressure, your doctor may consider:
Never stop blood pressure medication suddenly without medical supervision. Sudden withdrawal can cause rebound hypertension, which may be dangerous.
Stopping guanfacine suddenly can cause:
These guanfacine side effects related to withdrawal can be more concerning than the medication itself.
If discontinuation is recommended, it should be done gradually under medical guidance.
There is limited information about guanfacine during breastfeeding.
Potential concerns include:
Your doctor may weigh the benefits of continued treatment against potential infant exposure.
When discussing guanfacine use during pregnancy, consider asking:
Clear communication helps reduce uncertainty.
Pregnancy care often involves balancing risks — not eliminating them entirely.
Consider:
For some women, the risks of untreated ADHD or uncontrolled blood pressure outweigh the theoretical risks of medication exposure.
For others, reducing or stopping medication may be reasonable.
There is no one-size-fits-all answer.
Contact a healthcare provider urgently if you experience:
These may indicate serious pregnancy complications unrelated to — or worsened by — medication.
Managing ADHD or high blood pressure during pregnancy requires careful decision-making. Guanfacine is not automatically unsafe — but it is not fully studied either. The right choice depends on your personal health history, symptom severity, and pregnancy risks.
Do not stop or start guanfacine on your own.
Most importantly, speak to a doctor about your specific situation — especially if you experience severe symptoms, blood pressure changes, fainting, chest pain, or anything that could be life-threatening. Your healthcare provider can help you weigh the benefits and risks and create a plan that protects both you and your baby.
(References)
* Kaelber, D. C., et al. (2023). Alpha-2 adrenergic agonists in pregnancy: A systematic review of safety and efficacy. *Journal of Clinical Hypertension (Greenwich, Conn.)*, 25(6), 578–588.
* D'Angelo, C., et al. (2023). Treatment of ADHD in pregnancy and lactation. *Expert Opinion on Drug Safety*, 22(10), 919–931.
* Gressel, M. A., et al. (2021). Pharmacological Management of ADHD During Pregnancy: A Systematic Review. *Journal of Attention Disorders*, 25(8), 1083–1094.
* Miodownik, S., et al. (2021). Safety of attention-deficit/hyperactivity disorder (ADHD) medications during pregnancy: A narrative review. *Journal of Clinical Psychopharmacology*, 41(3), 291–299.
* Pasternak, M., et al. (2018). Pharmacological treatment of ADHD in pregnant women: a systematic review. *Journal of Psychopharmacology (Oxford, England)*, 32(9), 947–955.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.